Evidence map›Paper›PMID 35031844›Full record

ArticleEuropean radiology2022

Avoiding contrast-enhanced sequences does not compromise the precision of the simplified MaRIA for the assessment of non-penetrating Crohn's disease activity.

Agnès Fernàndez-Clotet, Víctor Sapena, Nunzia Capozzi, Sonia Rodríguez, Maria-Carme Masamunt, Elena Ricart, Ingrid Ordás, Julian Panés, Jordi Rimola

Abstract read
PubMed Publisher
In one paragraph

Article in European radiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Agnès Fernàndez-ClotetGastroenterology Department, IBD Unit, Hospital Clínic de Barcelona, Barcelona, Spain.
Víctor SapenaStatistics Core, Institut d'Investigació Biomèdica August Pi I Sunyer (IDIBAPS), Barcelona, Spain.
Nunzia CapozziRadiology Department, IBD Unit, Hospital Clínic de Barcelona, C/Villarroel, 170, 08036, Barcelona, Catalonia, Spain.
Sonia RodríguezRadiology Department, IBD Unit, Hospital Clínic de Barcelona, C/Villarroel, 170, 08036, Barcelona, Catalonia, Spain.
Maria-Carme MasamuntGastroenterology Department, IBD Unit, Hospital Clínic de Barcelona, Barcelona, Spain.
Elena RicartGastroenterology Department, IBD Unit, Hospital Clínic de Barcelona, Barcelona, Spain.
Ingrid OrdásGastroenterology Department, IBD Unit, Hospital Clínic de Barcelona, Barcelona, Spain.
Julian PanésGastroenterology Department, IBD Unit, Hospital Clínic de Barcelona, Barcelona, Spain.
Jordi RimolaRadiology Department, IBD Unit, Hospital Clínic de Barcelona, C/Villarroel, 170, 08036, Barcelona, Catalonia, Spain. jrimola@clinic.cat.ORCID http://orcid.org/0000-0002-1814-4198
Hospital Clínic de Barcelona · ESConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESIRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesPatients with Crohn's disease (CD) require multiple assessments with magnetic resonance enterography (MRE) from a young age. Standard MRE protocols for CD include contrast-enhanced sequences. Gadolinium deposits in brain tissue suggest avoiding gadolinium could benefit patients with CD. This study aimed to compare the accuracy of the simplified Magnetic Resonance Index of Activity (sMaRIA) calculated with and without contrast-enhanced sequences in determining the response to biologic drugs in patients with CD.

methodsThis post hoc analysis of a prospective study included patients with CD with endoscopic ulceration in ≥ 1 intestinal segment starting biologic drug therapy. Two blinded radiologists used the sMaRIA to score images obtained at baseline and week 46 of treatment first using only unenhanced sequences (T2-sMaRIA) and 1 month later using both unenhanced and enhanced images (CE-sMaRIA). We calculated the rates of agreement between T2-sMaRIA, CE-sMaRIA, and ileocolonoscopy for different conceptualizations of therapeutic response.

resultsA total of 46 patients (median age, 36 years [IQR: 28-47]) were included. Agreement with ileocolonoscopy was similar for CE-sMaRIA and T2-sMaRIA in identifying ulcer healing (kappa = 0.74 [0.55-0.93] and 0.70 [0.5-0.9], respectively), treatment response (kappa = 0.53 [0.28-0.79] and 0.44 [0.17 - 0.71]), and remission (kappa = 0.48 [0.22-0.73] and 0.43 [0.17-0.69]). The standardized effect size was moderate for both CE-sMaRIA = 0.63 [0.41-0.85] p < 0.001 and T2-sMaRIA = 0.58 [0.36-0.80] p < 0.001.

conclusionssMaRIA with and without contrast-enhanced images accurately classified the response according to different therapeutic endpoints determined by ileocolonoscopy. KEY POINTS: • The simplified Magnetic Resonance Index of Activity is accurate for the assessment of Crohn's disease activity, severity, and therapeutic response, using four dichotomic components that can be evaluated without the need of using contrast-enhanced sequences, representing a practical and safety advantage, but concerns have been expressed as to whether the lack of contrast sequences may compromise precision. • The simplified Magnetic Resonance Index of Activity can assess the response to biologic therapy in patients with Crohn's disease without the need for intravenous contrast agents obtaining comparable results without and with contrast-enhanced sequences. • Avoiding intravenous contrast agents could reduce the duration of the MRE examination and its cost and would increase the acceptance and safety of MRE in clinical research in patients with Crohn's disease.

Indexed as

Crohn DiseaseAdultContrast MediaGadoliniumHumansMagnetic Resonance ImagingProspective StudiesContrast MediaGadoliniumCrohn’s diseaseGadoliniumMagnetic resonance enterographySimplified MaRIATherapeutic response

Identifiers

PMID35031844
OpenAlexW4205933998

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.